Concord Biotech vs Divis Laboratories
Side-by-side stock comparison based on AI earnings call analysis
Which stock has stronger management signals?
Concord Biotech currently has the stronger revenue growth signal.
Concord Biotech and Divis Laboratories show active capex signals based on earnings call analysis.
No strong fundraising signal is currently visible for either company.
| Metric | Concord Biotech | Divis Laboratories |
|---|---|---|
| Current Price | ₹1,163.5 | ₹9,945.5 |
| Market Cap | ₹12,172.09 Cr. | ₹2.64 L Cr. |
| Industry | Pharmaceuticals & Biotechnology | Pharmaceuticals & Biotechnology |
| P/E Ratio | 42.81 | 88.61 |
| ROE (%) | 12.57 | 16.53 |
| Debt/Equity | — | — |
| Sales Growth 5Y (%) | 11.33 | 8.67 |
| Profit Growth 5Y (%) | 28.29 | 47.05 |
| Promoter Holding (%) | 44.09 | 51.87 |
| Revenue Rank | Rank 2 | Rank 3 |
| Margin Rank | Rank 1 | Rank 3 |
| Signal | — | — |
| Capex | Yes | Yes |
| Fundraise | No information | No information |
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.